Companies Organogenesis Holdings Inc.
Organogenesis (ORGO): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Organogenesis Holdings Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers35th pct.Of 20 peer CEOs
CEO pay, last three years
- $6,244,671FY2023
- $6,993,679FY2024
- $6,811,754FY2025
CEO total pay was $6,811,754 in fiscal 2025, down from $6,993,679 in fiscal 2024.
FY2025: salary $979,105 · bonus $0 · stock awards $2,833,330 · option awards $1,380,017
Executives and directors
David Francisco · CFOGary Gillheeney · CEOBrian Grow · CCOLori Freedman · ExecutivePatrick Bilbo · COOAlan A. Ades · Former director (through FY2025)Arthur S. Leibowitz · Independent DirectorDavid Erani · Former director (through FY2025)Garrett Lustig · Independent DirectorGilberto Quintero · Independent DirectorGlenn H. Nussdorf · DirectorJon Giacomin · Independent DirectorMichael J. Driscoll · Independent DirectorMichele Korfin · Independent DirectorPrathyusha Duraibabu · Independent DirectorRobert Ades · Director
Frequently asked questions
Who was the highest-paid executive at Organogenesis Holdings Inc. in fiscal 2025?
As disclosed, Gary Gillheeney (President and Chief Executive Officer) was the highest-paid executive at Organogenesis Holdings Inc. in fiscal 2025, with total compensation of $6,811,754.
How does Organogenesis Holdings Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Gary Gillheeney's total compensation ranked at the 35th percentile of Organogenesis Holdings Inc.'s disclosed peer group.
What is Organogenesis Holdings Inc.'s CEO-to-median employee pay ratio?
As disclosed, Organogenesis Holdings Inc.'s CEO-to-median employee pay ratio was 17:1.
How did shareholders vote on Organogenesis Holdings Inc.'s executive compensation?
As disclosed, 85.07% of shareholders supported Organogenesis Holdings Inc.'s executive compensation in the latest say-on-pay vote.
How much does Organogenesis Holdings Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Organogenesis Holdings Inc. reported total board compensation of $1,827,308 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Gary Gillheeney | $979,105 | $0 | $2,833,330 | $1,380,017 | $1,536,575 | $0 | $82,727 | $6,811,754 |
| President and Chief Executive Officer | ||||||||
| Brian Grow | 485,123 | 0 | 732,390 | 360,241 | 518,366 | 0 | 47,370 | 2,143,490 |
| Chief Commercial Officer | ||||||||
| Patrick Bilbo | 514,478 | 0 | 736,665 | 362,317 | 441,377 | 0 | 62,091 | 2,116,928 |
| Chief Operating Officer | ||||||||
| Lori Freedman | 518,838 | 0 | 648,295 | 319,422 | 513,081 | 0 | 43,243 | 2,042,879 |
| Chief Administrative and Legal Officer | ||||||||
| David Francisco | 514,626 | 0 | 660,731 | 325,459 | 445,466 | 0 | 40,783 | 1,987,065 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Gary Gillheeney | $6,811,754 | $6,993,679 | $6,244,671 | ↓ −181,925 |
| Brian Grow | 2,143,490 | 2,094,553 | 1,924,658 | ↑ +48,937 |
| Patrick Bilbo | 2,116,928 | 2,276,634 | 2,156,855 | ↓ −159,706 |
| Lori Freedman | 2,042,879 | 1,995,053 | 1,994,853 | ↑ +47,826 |
| David Francisco | 1,987,065 | 2,025,754 | 1,629,294 | ↓ −38,689 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The compensation of our executive officers is determined by our board of directors based upon the recommendation of our compensation committee, aiming to attract and retain talent through competitive pay.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Gary Gillheeney | RSU | 2025-02-19 | — | — | 708,215 | — | $2,499,999 |
| Brian Grow | PSU | 2025-02-19 | 12,204 | 24,409 | — | 48,818 | 86,164 |
| Patrick Bilbo | RSU | 2025-02-19 | — | — | 184,136 | — | 650,000 |
| Lori Freedman | PSU | 2025-02-19 | 10,803 | 21,606 | — | 43,212 | 76,269 |
| Lori Freedman | RSU | 2025-02-19 | — | — | 162,047 | — | 572,026 |
| Brian Grow | RSU | 2025-02-19 | — | — | 183,067 | — | 646,227 |
| David Francisco | PSU | 2025-02-19 | 11,010 | 22,020 | — | 44,040 | 77,731 |
| Gary Gillheeney | PSU | 2025-02-19 | 47,214 | 94,428 | — | 188,856 | 333,331 |
| David Francisco | RSU | 2025-02-19 | — | — | 165,156 | — | 583,001 |
| Patrick Bilbo | PSU | 2025-02-19 | 12,275 | 24,551 | — | 49,102 | 86,665 |
| Gary Gillheeney | OPTION | 2025-02-19 | — | — | 732,596 | — | 1,380,017 |
| Lori Freedman | OPTION | 2025-02-19 | — | — | 167,625 | — | 319,422 |
| Brian Grow | OPTION | 2025-02-19 | — | — | 189,369 | — | 360,241 |
| David Francisco | OPTION | 2025-02-19 | — | — | 170,841 | — | 325,459 |
| Patrick Bilbo | OPTION | 2025-02-19 | — | — | 190,475 | — | 362,317 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Gary Gillheeney | $2,499,999 | $333,331 | $1,380,017 | 7.9% |
| Brian Grow | 646,227 | 86,164 | 360,241 | 7.9% |
| Patrick Bilbo | 650,000 | 86,665 | 362,317 | 7.9% |
| Lori Freedman | 572,026 | 76,269 | 319,422 | 7.9% |
| David Francisco | 583,001 | 77,731 | 325,459 | 7.9% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| David Francisco | Option | 23,923 | 8.03 | — |
| Lori Freedman | Option | 24,809 | 8.03 | — |
| Brian Grow | Option | 26,766 | 8.03 | — |
| Patrick Bilbo | Option | 31,380 | 8.03 | — |
| Lori Freedman | PSU | 43,212 | — | 223,838 |
| David Francisco | PSU | 44,040 | — | 228,127 |
| Brian Grow | PSU | 48,818 | — | 252,877 |
| Patrick Bilbo | PSU | 49,102 | — | 254,348 |
| David Francisco | Option | 143,946 | 2.51 | — |
| Lori Freedman | Option | 165,538 | 2.51 | — |
| Gary Gillheeney | Option | 166,133 | 8.03 | — |
| Lori Freedman | Option | 167,625 | 3.53 | — |
| David Francisco | Option | 170,841 | 3.53 | — |
| Brian Grow | Option | 172,735 | 2.51 | — |
| Gary Gillheeney | PSU | 188,856 | — | 978,274 |
| Brian Grow | Option | 189,369 | 3.53 | — |
| Patrick Bilbo | Option | 190,475 | 3.53 | — |
| Patrick Bilbo | Option | 194,327 | 2.51 | — |
| Lori Freedman | Option | 207,553 | 3.43 | — |
| David Francisco | Option | 217,437 | 3.43 | — |
| Brian Grow | Option | 235,227 | 3.43 | — |
| Patrick Bilbo | Option | 254,006 | 3.43 | — |
| David Francisco | RSU | 416,760 | — | 2,158,817 |
| Lori Freedman | RSU | 426,746 | — | 2,210,544 |
| Brian Grow | RSU | 469,960 | — | 2,434,393 |
| Patrick Bilbo | RSU | 501,550 | — | 2,598,029 |
| Gary Gillheeney | Option | 732,596 | 3.53 | — |
| Gary Gillheeney | Option | 827,691 | 2.51 | — |
| Gary Gillheeney | Option | 929,047 | 3.43 | — |
| Gary Gillheeney | RSU | 1,740,321 | — | 9,014,863 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Arthur S. LeibowitzIndependent · Compensation · Nominating/Governance · Audit (Chair) | $138,606 | $175,000 | — | — | — | $313,606 |
| Jon GiacominIndependent · Compensation · Nominating/Governance (Chair) · Audit | 94,808 | 175,000 | — | — | — | 269,808 |
| Garrett LustigIndependent · Compensation · Nominating/Governance · Research & Development | 77,500 | 175,000 | — | — | — | 252,500 |
| Michele KorfinIndependent · Compensation · Research & Development | 75,192 | 175,000 | — | — | — | 250,192 |
| Prathyusha DuraibabuIndependent · Compensation · Research & Development · Audit | 74,808 | 175,000 | — | — | — | 249,808 |
| Gilberto QuinteroIndependent · Nominating/Governance · Research & Development (Chair) · Audit | 73,702 | 175,000 | — | — | — | 248,702 |
| Michael J. DriscollIndependent · Nominating/Governance · Audit | 67,692 | 175,000 | — | — | — | 242,692 |
| Alan A. AdesIndependent · Not standing for re-election · Departed during FY | 0 | 0 | 0 | — | 0 | 0 |
| Robert AdesNot independent | 0 | 0 | 0 | — | 0 | 0 |
| Gary S. Gillheeney SrEmployee director | — | — | — | — | — | 0 |
| David EraniIndependent · Not standing for re-election · Departed during FY | 0 | 0 | 0 | — | 0 | 0 |
| Glenn H. NussdorfNot independent | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $55,000 |
|---|---|
| Annual equity retainer | $175,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 40,000 / 20,000 / 15,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $602,308 |
| Equity awards (grant-date value) | $1,225,000 |
| All other compensation | $0 |
| Total cost of the board | $1,827,308 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Organogenesis as a peer
Companies that benchmark against ORGO
5 companies name ORGO as a compensation peer
The list of companies that name ORGO as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
BVS Bioventus Inc.IART Integra LifeSciences Holdings CorporationAXGN AxoGen, Inc.MDXG MiMedx Group, Inc.OFIX Orthofix Medical Inc.ANGO AngioDynamics, Inc.FNA Paragon 28, Inc.NVRO Nevro Corp.ZIMV ZimVie Inc.AVNS Avanos Medical, Inc.CNMD CONMED CorporationVNDA Vanda Pharmaceuticals Inc.ATRC AtriCure, Inc.PCRX Pacira BioSciences, Inc.EMBC Embecta Corp.TCMD Tactile Systems Technology, Inc.ATEC Alphatec Holdings, Inc.ANIK Anika Therapeutics, Inc.AORT Artivion, IncOSUR OraSure Technologies, Inc.
Peer reciprocity
The companies Organogenesis Holdings Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Pacira BioSciences, Inc. | 2025 | Frank Lee | $935,308 | $9,215,500 | $0 | $738,810 | $11,636,917 |
| 2 | Nevro Corp. | 2023 | Kevin Thornal | 515,625 | 10,080,173 | 0 | 402,750 | 11,453,548 |
| 3 | Alphatec Holdings, Inc. | 2025 | Patrick Miles | 762,000 | 8,859,650 | 0 | 600,000 | 10,260,507 |
| 4 | Avanos Medical, Inc. | 2025 | David Pacitti | 751,705 | 7,000,000 | 0 | 1,148,667 | 9,469,803 |
| 5 | Embecta Corp. | 2025 | Devdatt Kurdikar | 976,923 | 7,000,008 | 0 | 1,399,540 | 9,400,088 |
| 6 | Integra LifeSciences Holdings Corporation | 2025 | Mojdeh Poul | 1,009,616 | 5,219,868 | 2,250,011 | 174,563 | 9,375,551 |
| 7 | AtriCure, Inc. | 2025 | Michael Carrel | 828,439 | 7,203,478 | 0 | 1,171,703 | 9,217,620 |
| 8 | AxoGen, Inc. | 2025 | Michael Dale | 775,865 | 7,342,895 | 0 | 906,133 | 9,047,454 |
| 9 | Conmed Corporation | 2025 | Patrick Beyer | 891,100 | 2,499,971 | 2,499,977 | 1,129,469 | 7,634,873 |
| 10 | Orthofix Medical Inc. | 2025 | Massimo Calafiore | 848,322 | 4,499,988 | 1,500,009 | 445,579 | 7,310,039 |
| 11 | ZimVie Inc. | 2024 | Vafa Jamali | 818,461 | 6,367,343 | 0 | 0 | 7,209,869 |
| 12 | MiMedx Group, Inc. | 2025 | Joseph Capper | 768,173 | 4,699,000 | 819,422 | 887,800 | 7,182,208 |
| 13 | Artivion, Inc | 2025 | J. Patrick Mackin | 835,145 | 5,006,990 | 0 | 991,368 | 6,883,108 |
| 14 | Organogenesis Holdings Inc. | 2025 | Gary Gillheeney | 979,105 | 2,833,330 | 1,380,017 | 1,536,575 | 6,811,754 |
| 15 | AngioDynamics, Inc. | 2026 | James Clemmer | 828,171 | 3,689,866 | 0 | 1,502,491 | 6,060,145 |
| 16 | Bioventus Inc. | 2025 | Robert Claypoole | 824,110 | 1,982,530 | 662,949 | 781,256 | 4,299,108 |
| 17 | OraSure Technologies, Inc. | 2025 | Carrie Eglinton Manner | 721,000 | 3,394,188 | 0 | 173,040 | 4,292,228 |
| 18 | Vanda Pharmaceuticals Inc. | 2025 | Mihael Polymeropoulos | 965,655 | 2,007,000 | 0 | 834,326 | 3,851,468 |
| 19 | Tactile Systems Technology, Inc. | 2025 | Sheri Dodd | 675,000 | 2,019,978 | 0 | 737,438 | 3,466,916 |
| 20 | Paragon 28, Inc. | 2023 | Albert DaCosta | 700,769 | 1,832,495 | 0 | 667,400 | 3,232,420 |
| 21 | Anika Therapeutics, Inc. | 2025 | Stephen Griffin | 500,000 | 1,215,222 | 0 | 0 | 2,033,370 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Organogenesis Holdings Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| Alphatec Holdings, Inc. | 157% | PSU 50 · RSU 50 | No | Compensia |
| AngioDynamics, Inc. | 180% | PSU 50 · RSU 50 | No | Meridian Compensation Partners, LLC |
| Anika Therapeutics, Inc. | 100% | PSU 67 · RSU 33 | No | Willis Towers Watson |
| Artivion, Inc | 118.7% | PSU 50 · RSU 50 | No | Willis Towers Watson |
| AtriCure, Inc. | not disclosed | PSU 70 · RSU 30 | No | Korn Ferry |
| Avanos Medical, Inc. | 139% | PSU 50 · RSU 25 · Options 25 | No | Meridian Compensation Partners |
| AxoGen, Inc. | 116.79% | PSU 50 · RSU 50 | No | Aon |
| Bioventus Inc. | not disclosed | RSU 49 · PSU 26 · Options 25 | No | Aon plc |
| Conmed Corporation | 126.8% | Options 50 · PSU 50 | Yes — rTSR | Compensia, Inc. |
| Embecta Corp. | 110.2% | not disclosed | No | Korn Ferry |
| Integra LifeSciences Holdings Corporation | 40% | PSU 50 · Options 25 · RSU 25 | No | WTW |
| MiMedx Group, Inc. | 115% | not disclosed | No | Willis Towers Watson |
| Nevro Corp. | 53.7% | not disclosed | No | Aon |
| OraSure Technologies, Inc. | 24.0% | RSU 50 · PSU 50 | Yes — Relative TSR performance vs peer group | Pay Governance |
| Orthofix Medical Inc. | 47.7% | PSU 50 · Option 25 · RSU 25 | No | Meridian |
| Pacira BioSciences, Inc. | 90% | RSU 80 · PSU 20 | No | Aon |
| Paragon 28, Inc. | 94% | RSU 100 | not disclosed | Compensia, Inc. |
| Tactile Systems Technology, Inc. | 115% | PSU 50 · RSU 50 | No | Aon Consulting, Inc. |
| Vanda Pharmaceuticals Inc. | 108% | not disclosed | Yes — Relative TSR | Willis Towers Watson |
| ZimVie Inc. | 0% | RSU 100 | not disclosed | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-15 | 72,516,011 | 12,722,258 | 61,328 | 85.07% | Passed |
| 2025 | 2025-06-23 | 67,071,290 | 6,289,601 | 98,174 | 91.43% | Passed |
| 2024 | 2024-06-20 | 63,842,175 | 5,876,101 | 8,451 | 91.57% | Passed |
| 2023 | 2023-06-13 | 51,710,250 | 13,676,178 | 64,553 | 79.08% | Passed |
| 2022 | 2022-06-23 | 91,740,768 | 12,563,596 | 280,169 | 87.95% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-15 | 85.07%a |
| 2025 | 2025-06-23 | 91.43%b |
| 2024 | 2024-06-20 | 91.57%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the voting outcome.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 17 : 1 |
|---|---|
| CEO total compensation | $6,811,754 |
| Median employee compensation | $411,028 |
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (63 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Gary Gillheeney. DEF 14A, filed 2026-04-30. Section “Summary Compensation Table for Fiscal Year 2025” · page 31. As printed: 6,811,754. View filing ↗
- Section 01, Brian Grow. DEF 14A, filed 2026-04-30. Section “Summary Compensation Table for Fiscal Year 2025”. As printed: 2,143,490. View filing ↗
- Section 01, Patrick Bilbo. DEF 14A, filed 2026-04-30. Section “Summary Compensation Table for Fiscal Year 2025”. As printed: 2,116,928. View filing ↗
- Section 01, Lori Freedman. DEF 14A, filed 2026-04-30. Section “Summary Compensation Table for Fiscal Year 2025”. As printed: 2,042,879. View filing ↗
- Section 01, David Francisco. DEF 14A, filed 2026-04-30. Section “Summary Compensation Table for Fiscal Year 2025”. As printed: 1,987,065. View filing ↗
- Section 03, Gary Gillheeney RSU. DEF 14A, filed 2026-04-30. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Grow PSU. DEF 14A, filed 2026-04-30. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Patrick Bilbo RSU. DEF 14A, filed 2026-04-30. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Lori Freedman PSU. DEF 14A, filed 2026-04-30. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Lori Freedman RSU. DEF 14A, filed 2026-04-30. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Grow RSU. DEF 14A, filed 2026-04-30. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, David Francisco PSU. DEF 14A, filed 2026-04-30. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Gary Gillheeney PSU. DEF 14A, filed 2026-04-30. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, David Francisco RSU. DEF 14A, filed 2026-04-30. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Patrick Bilbo PSU. DEF 14A, filed 2026-04-30. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Gary Gillheeney OPTION. DEF 14A, filed 2026-04-30. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Lori Freedman OPTION. DEF 14A, filed 2026-04-30. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Grow OPTION. DEF 14A, filed 2026-04-30. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, David Francisco OPTION. DEF 14A, filed 2026-04-30. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Patrick Bilbo OPTION. DEF 14A, filed 2026-04-30. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-30. Section “CEO Pay Ratio”. As printed: 17 : 1. View filing ↗
- Section 08, Arthur S. Leibowitz. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 313,606. View filing ↗
- Section 08, Jon Giacomin. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 269,808. View filing ↗
- Section 08, Garrett Lustig. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 252,500. View filing ↗
- Section 08, Michele Korfin. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 250,192. View filing ↗
- Section 08, Prathyusha Duraibabu. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 249,808. View filing ↗
- Section 08, Gilberto Quintero. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 248,702. View filing ↗
- Section 08, Michael J. Driscoll. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 242,692. View filing ↗
- Section 08, Alan A. Ades. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Robert Ades. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Gary S. Gillheeney Sr. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, David Erani. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Glenn H. Nussdorf. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-16. Item 5.07 · say-on-pay result. As reported: 85.07% (votes for as printed: 72,516,011). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-24. Item 5.07 · say-on-pay result. As reported: 91.43% (votes for as printed: 67,071,290). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-21. Item 5.07 · say-on-pay result. As reported: 91.57% (votes for as printed: 63,842,175). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 602,308 + equity 1,225,000 + all other 0 = 1,827,308, summed across the director compensation table rows.
- Pacira BioSciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Pacira BioSciences, Inc.'s own proxy. As printed: 11,636,917. View filing ↗
- Nevro Corp., Section 10b CEO total. DEF 14A, filed 2024-04-12. CEO total compensation as printed in Nevro Corp.'s own proxy. As printed: 11,453,548. View filing ↗
- Alphatec Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Alphatec Holdings, Inc.'s own proxy. As printed: 10,260,507. View filing ↗
- Avanos Medical, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-12. CEO total compensation as printed in Avanos Medical, Inc.'s own proxy. As printed: 9,469,803. View filing ↗
- Embecta Corp., Section 10b CEO total. DEF 14A, filed 2025-12-18. CEO total compensation as printed in Embecta Corp.'s own proxy. As printed: 9,400,088. View filing ↗
- Integra LifeSciences Holdings Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Integra LifeSciences Holdings Corporation's own proxy. As printed: 9,375,551. View filing ↗
- AtriCure, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in AtriCure, Inc.'s own proxy. As printed: 9,217,620. View filing ↗
- AxoGen, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in AxoGen, Inc.'s own proxy. As printed: 9,047,454. View filing ↗
- Conmed Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Conmed Corporation's own proxy. As printed: 7,634,873. View filing ↗
- Orthofix Medical Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Orthofix Medical Inc.'s own proxy. As printed: 7,310,039. View filing ↗
- ZimVie Inc., Section 10b CEO total. DEF 14A, filed 2025-03-25. CEO total compensation as printed in ZimVie Inc.'s own proxy. As printed: 7,209,869. View filing ↗
- MiMedx Group, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in MiMedx Group, Inc.'s own proxy. As printed: 7,182,208. View filing ↗
- Artivion, Inc, Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Artivion, Inc's own proxy. As printed: 6,883,108. View filing ↗
- Organogenesis Holdings Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Organogenesis Holdings Inc.'s own proxy. As printed: 6,811,754. View filing ↗
- AngioDynamics, Inc., Section 10b CEO total. DEF 14A, filed 2026-10-08. CEO total compensation as printed in AngioDynamics, Inc.'s own proxy. As printed: 6,060,145. View filing ↗
- Bioventus Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Bioventus Inc.'s own proxy. As printed: 4,299,108. View filing ↗
- OraSure Technologies, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in OraSure Technologies, Inc.'s own proxy. As printed: 4,292,228. View filing ↗
- Vanda Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Vanda Pharmaceuticals Inc.'s own proxy. As printed: 3,851,468. View filing ↗
- Tactile Systems Technology, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Tactile Systems Technology, Inc.'s own proxy. As printed: 3,466,916. View filing ↗
- Paragon 28, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-05. CEO total compensation as printed in Paragon 28, Inc.'s own proxy. As printed: 3,232,420. View filing ↗
- Anika Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Anika Therapeutics, Inc.'s own proxy. As printed: 2,033,370. View filing ↗
- Section 10a, MiMedx Group, Inc. reciprocity. DEF 14A. MiMedx Group, Inc. names Organogenesis Holdings Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Pacira BioSciences, Inc. reciprocity. DEF 14A. Pacira BioSciences, Inc. names Organogenesis Holdings Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Anika Therapeutics, Inc. reciprocity. DEF 14A. Anika Therapeutics, Inc. names Organogenesis Holdings Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗